- Home
- TRDA vs VNDA Comparison
TRDA vs VNDA Comparison
Compare TRDA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- VNDA
- Stock Information
- Founded
- TRDA 2016
- VNDA 2002
- Country
- TRDA United States
- VNDA United States
- Employees
- TRDA N/A
- VNDA N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- TRDA Health Care
- VNDA Health Care
- Exchange
- TRDA Nasdaq
- VNDA Nasdaq
- Market Cap
- TRDA 264.5M
- VNDA 286.4M
- IPO Year
- TRDA 2021
- VNDA 2006
- Fundamental
- Price
- TRDA $6.64
- VNDA $4.67
- Analyst Decision
- TRDA Strong Buy
- VNDA Strong Buy
- Analyst Count
- TRDA 3
- VNDA 3
- Target Price
- TRDA $25.67
- VNDA $15.33
- AVG Volume (30 Days)
- TRDA 127.9K
- VNDA 459.2K
- Earning Date
- TRDA 08-12-2025
- VNDA 07-31-2025
- Dividend Yield
- TRDA N/A
- VNDA N/A
- EPS Growth
- TRDA N/A
- VNDA N/A
- EPS
- TRDA 0.61
- VNDA N/A
- Revenue
- TRDA $172,220,000.00
- VNDA $201,351,000.00
- Revenue This Year
- TRDA N/A
- VNDA $16.86
- Revenue Next Year
- TRDA N/A
- VNDA $39.78
- P/E Ratio
- TRDA $10.80
- VNDA N/A
- Revenue Growth
- TRDA 5.74
- VNDA 13.37
- 52 Week Low
- TRDA $6.12
- VNDA $3.81
- 52 Week High
- TRDA $21.79
- VNDA $6.04
- Technical
- Relative Strength Index (RSI)
- TRDA 47.73
- VNDA 47.29
- Support Level
- TRDA $6.18
- VNDA $4.60
- Resistance Level
- TRDA $6.67
- VNDA $4.85
- Average True Range (ATR)
- TRDA 0.34
- VNDA 0.19
- MACD
- TRDA 0.04
- VNDA -0.03
- Stochastic Oscillator
- TRDA 66.67
- VNDA 15.91
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.